Marinus Finds Silver Lining In Ganaxolone Trial Miss
The biotech announces another poor performance for its lead drug candidate, but puts a positive spin on the data and plans continued development.
You may also be interested in...
Phase II results for Marinus’s ganaxolone in postpartum depression are a mixed bag, but the US biotech sees potential in this and other neurological indications, probably with partners.
The biotech vows to continue development of the drug in pediatric indications after a late-stage failure in an adult seizure disorder.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.